VTGN vs. PGEN, TNGX, SNDL, TRVI, CMRX, BTMD, LFVN, VYGR, ITOS, and AQST
Should you be buying Vistagen Therapeutics stock or one of its competitors? The main competitors of Vistagen Therapeutics include Precigen (PGEN), Tango Therapeutics (TNGX), SNDL (SNDL), Trevi Therapeutics (TRVI), Chimerix (CMRX), biote (BTMD), LifeVantage (LFVN), Voyager Therapeutics (VYGR), iTeos Therapeutics (ITOS), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry.
Vistagen Therapeutics vs.
Precigen (NASDAQ:PGEN) and Vistagen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, community ranking and risk.
Vistagen Therapeutics has lower revenue, but higher earnings than Precigen. Vistagen Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.
Precigen received 153 more outperform votes than Vistagen Therapeutics when rated by MarketBeat users. However, 72.31% of users gave Vistagen Therapeutics an outperform vote while only 67.34% of users gave Precigen an outperform vote.
Precigen has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Comparatively, Vistagen Therapeutics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500.
Precigen presently has a consensus price target of $6.33, suggesting a potential upside of 470.57%. Given Precigen's higher probable upside, equities research analysts clearly believe Precigen is more favorable than Vistagen Therapeutics.
Precigen has a net margin of -3,521.68% compared to Vistagen Therapeutics' net margin of -4,521.71%. Vistagen Therapeutics' return on equity of -36.35% beat Precigen's return on equity.
In the previous week, Precigen had 6 more articles in the media than Vistagen Therapeutics. MarketBeat recorded 7 mentions for Precigen and 1 mentions for Vistagen Therapeutics. Precigen's average media sentiment score of 0.32 beat Vistagen Therapeutics' score of -0.86 indicating that Precigen is being referred to more favorably in the media.
33.5% of Precigen shares are owned by institutional investors. Comparatively, 78.4% of Vistagen Therapeutics shares are owned by institutional investors. 44.9% of Precigen shares are owned by insiders. Comparatively, 1.3% of Vistagen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Precigen beats Vistagen Therapeutics on 11 of the 19 factors compared between the two stocks.
Get Vistagen Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vistagen Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VTGN) was last updated on 1/20/2025 by MarketBeat.com Staff
Free VTGN Stock Alerts